Scholarlink

<p>Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation and is thought to result from interactions among the immune system, environmental factors, and the gut microbiota in genetically susceptible individuals. <i>Akkermansia muciniphila</i>, a commensal bacterium has been reported to be depleted in individuals with IBD, although its precise role in intestinal inflammation remains unclear. This study examined the effects of <i>A. muciniphila</i> across multiple models of colitis, including dextran sulphate sodium (DSS)-induced colitis, the Mucin-2 knockout (<i>Muc2</i><sup>−/−</sup>) model of spontaneous colitis, and <i>Trichuris muris-</i>mediated infectious colitis. In a DSS recovery model, treatment with pasteurized <i>A. muciniphila</i> reduced the severity of inflammation. However, when administered prior to DSS exposure, both live and pasteurized bacteria did not significantly reduce inflammatory markers, suggesting limited preventive effects. In <i>T. muris</i>–infected mice, supplementation with live <i>A. muciniphila</i> increased Th2 and anti-inflammatory cytokine responses, reduced parasite burden, and enhanced gene expression of the mucin <i>Muc5ac</i>. Additionally, both live and pasteurized <i>A. muciniphila</i> alleviated spontaneous colitis severity in <i>Muc2</i><sup>−/−</sup> mice, indicating that these protective effects occur independently of Muc2. These findings expand understanding of the role of <i>A. muciniphila</i> in intestinal inflammation and highlight its potential as a therapeutic target for inflammatory intestinal disorders such as IBD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Akkermansia muciniphila supplementation alters inflammatory profiles across diverse models of colitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月30日

查看全文
  • Jensine A. Grondin,
  • Huaqing Wang,
  • Sabah Haq,
  • Charissa Cheng,
  • Hooman Derakhshani,
  • Lesley MacNeil,
  • Michael G. Surette,
  • Waliul I. Khan

摘要

Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation and is thought to result from interactions among the immune system, environmental factors, and the gut microbiota in genetically susceptible individuals. Akkermansia muciniphila, a commensal bacterium has been reported to be depleted in individuals with IBD, although its precise role in intestinal inflammation remains unclear. This study examined the effects of A. muciniphila across multiple models of colitis, including dextran sulphate sodium (DSS)-induced colitis, the Mucin-2 knockout (Muc2−/−) model of spontaneous colitis, and Trichuris muris-mediated infectious colitis. In a DSS recovery model, treatment with pasteurized A. muciniphila reduced the severity of inflammation. However, when administered prior to DSS exposure, both live and pasteurized bacteria did not significantly reduce inflammatory markers, suggesting limited preventive effects. In T. muris–infected mice, supplementation with live A. muciniphila increased Th2 and anti-inflammatory cytokine responses, reduced parasite burden, and enhanced gene expression of the mucin Muc5ac. Additionally, both live and pasteurized A. muciniphila alleviated spontaneous colitis severity in Muc2−/− mice, indicating that these protective effects occur independently of Muc2. These findings expand understanding of the role of A. muciniphila in intestinal inflammation and highlight its potential as a therapeutic target for inflammatory intestinal disorders such as IBD.